에 대한 최신 뉴스 TransMedics Gr (NASDAQ:TMDX) 주식

TransMedics Gr

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

TransMedics Group

Earnings

News

Guidance

Health Care

After-Hours Center

Movers

TMDX

트랜스메딕스 그룹(NASDAQ:TMDX) 주식은 회사가 예상보다 저조한 2024년 3분기 재무 결과를 발표한 후 월요일 애프터 마켓에서 22% 이상 급락했다.

트랜스메딕스 그룹의 주식은 부진한 3분기 실적으로 시간외 거래에서 22% 이상 급락

TransMedics Group Inc

Macro Economic Events

Econ #s

Economics

France Harmonised Index of Consumer Prices (MoM) For October 0.3% Vs. 0.3% Est.; -1.3% Prior

France Consumer Price Index (MoM) For October 0.3% Vs. 0.2% Est.; -1.3% Prior

OneStream, Inc announced today the pricing of the previously announced underwritten public offering of 15,000,000 shares of its Class&nbsp;A common stock, at a public offering price of $31.00 per share, of which 9,006,948 shares will be sold by selling stockholders and 5,993,052 shares will be sold by OneStream as part of a non-dilutive "synthetic secondary" transaction (the "Synthetic Secondary").

Reported Earlier, OneStream Prices Secondary Offering Of 15M Class A Common Stock At $31/Share

Associated expects to use the net proceeds from this offering for general corporate purposes to support continued organic growth and capital generation, which may include investments in Associated Bank, N.A. and potential balance sheet optimization strategies.

Reported Earlier, Associated Banc-Corp Prices $300M Public Offering Of 12M Common Stock Offering At $25/Share

In a unique perspective, a cryptocurrency analyst equated Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to gunpowder, arguing that sooner or later sovereign nations would be compelled to adopt the leading cryptocurrency.
What Happened: Matt Huang, CEO of cryptocurrency-focused investment firm Paradigm, penned a blog post Thursday, highlighting Bitcoin&#8217;s growing prominence. 
Huang argued that like gunpowder became indispensable after its discovery, the same would eventually pan out for emerging technologies like artificial intelligence, drones, and Bitcoin.
&#8220;Sovereigns can no longer afford to dismiss BTC. From a game theoretic perspective, BTC is like gunpowder, not the iPhone. Christopher,&#8221; the analyst remarked.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Bitcoin for the Sovereign <a href="https://t.co/HD1UpcD6J7">pic.twitter.com/HD1UpcD6J7</a>
&mdash; Matt Huang (@matthuang) <a href="https://twitter.com/matthuang/status/1857127295145902586?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Huang highlighted how calls for the establishment of a Bitcoin strategic reserve have intensified since Donald Trump&#8217;s presidential victory, suggesting the opening of the Overton window for Bitcoin acceptance in America.
&#8220;Sovereigns that build BTC reserves early will benefit from significantly better entry prices. The race to build BTC reserves is on.&#8221;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41912787/buckle-up-for-the-bull-markets-most-fun-phase-says-industry-expert-bitcoin-ethereum-dogecoin-about-to-enter-the-euphoria-stage?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;Buckle Up&#8217; For The Bull Market&#8217;s &#8216;Most Fun Phase,&#8217; Says Industry Expert: Bitcoin, Ethereum, Dogecoin Abo</a>
Why It Matters: The Republican side vigorously promoted the idea of a Bitcoin reserve leading up to the elections, with none other than President-elect Trump <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/40001426/trump-aims-to-make-us-crypto-capital-of-the-planet-well-get-it-done">vowing to establish one</a> if voted to power.
A few days later, Senator Cynthia Lummis (R-Wyo.) <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/40087880/cynthia-lummis-unveils-strategic-bitcoin-reserve-legislation-this-is-our-louisiana-purchas">proposed </a>a bill, called the BITCOIN Act, aimed at creating a strategic Bitcoin stockpile to support America's balance sheet.
The senator reiterated her pledge following the Republican Party&#8217;s electoral triumph last week, as Polymarket odds showed a <a href="https://polymarket.com/event/will-trump-create-a-national-bitcoin-reserve-in-his-first-100-days?tid=1731494882651">35%</a> probability of this happening.
Moreover, emboldened by broader support, Pennsylvania introduced the <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41986427/pennsylvania-introduces-bitcoin-strategic-reserve-act-to-invest-up-to-700-million-in-btc">Bitcoin Strategic Reserve Act</a>, hoping to build its own state-held Bitcoin reserve.
Price Action: At the time of writing, Bitcoin was trading at $87,824.55, down 2.35% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA.." target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/41998869/analyst-says-bitcoin-lives-rent-free-in-peoples-minds-after-peter-schiffs-cheeky-social-security-trust-remark">Peter Schiff&#8217;s Cheeky Bitcoin Turnaround Post Earns Reaction From Popular Analyst: &#8216;You Buy It And Become Rich Or You Keep Hating And Turn Crazy&#8217;</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

Bitcoin Is Like Gunpowder And That Is Why Sovereign States Can't Refuse Its Adoption, Says Crypto Analyst

Buybacks

SNDL

Reported Earlier, SNDL Extends Share Repurchase Program With C$100M Authorization, Aiming To Repurchase Up To 13.2M Shares

Equus Total Return, Inc. (NYSE:<a href="https://www.benzinga.com/stock/EQS#NYSE">EQS</a>) ("Equus" or the "Company") reports net assets as of September 30, 2024, of $40.2 million. Net asset value per share decreased to $2.96 as of September 30, 2024, from $3.66 as of June 30, 2024. Comparative data is summarized below (in thousands, except per share amounts):&nbsp;&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>As of the Quarter Ended</td>
<td>9/30/2024</td>
<td>6/30/2024</td>
<td>3/31/2024</td>
<td>12/31/2023</td>
<td>9/30/2023 &nbsp;</td>
</tr>
<tr>
<td>Net assets</td>
<td>$40,165</td>
<td>$49,792</td>
<td>$45,892</td>
<td>$48,287</td>
<td>$47,128</td>
</tr>
<tr>
<td>Shares outstanding</td>
<td>13,586</td>
<td>13,586</td>
<td>13,586</td>
<td>13,586</td>
<td>13,518</td>
</tr>
<tr>
<td>Net assets per share</td>
<td>$2.96</td>
<td>$3.66</td>
<td>$3.38</td>
<td>$3.55</td>
<td>$3.49</td>
</tr>
</tbody>
</table>
</figure>

Reported Earlier, Equus Total Return Reports Net Assets As Of September 30, 2024, Of $40.2M; Net Asset Value Per Share $2.96

ZLAB

Reported Earlier, Zai Lab Prices 7.8M American Depositary Shares At $25.50/ADS In $200M Public Offering

Maui Land &amp; Pineapple Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLP#NYSE">MLP</a>) reported quarterly losses of $(0.07) per share. This is a 16.67 percent decrease over losses of $(0.06) per share from the same period last year. The company reported $3.02 million in sales this quarter. This is a 43.98 percent increase over sales of $2.10 million the same period last year.

Maui Land & Pineapple Co Q3 EPS $(0.07) Down From $(0.06) YoY, Sales $3.02M Up From $2.10M YoY

GreenPower Motor Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GP#NASDAQ">GP</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.16) by 12.5 percent. The company reported quarterly sales of $5.347 million which missed the analyst consensus estimate of $7.967 million by 32.88 percent. This is a 36.35 percent decrease over sales of $8.400 million the same period last year.

Earnings Misses

GreenPower Motor Co Q2 2025 GAAP EPS $(0.18) Misses $(0.16) Estimate, Sales $5.347M Miss $7.967M Estimate

Beam Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEEM#NASDAQ">BEEM</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.12) by 175 percent. The company reported quarterly sales of $11.482 million which missed the analyst consensus estimate of $18.863 million by 39.13 percent. This is a 30.35 percent decrease over sales of $16.486 million the same period last year.

Earnings Beats

BEEM

Beam Global Q3 2024 GAAP EPS $0.09 Beats $(0.12) Estimate, Sales $11.482M Miss $18.863M Estimate

Lantmännen will invest more than 100 million euros in a state-of–the-art <a href="https://www.globenewswire.com/Tracker?data=D-7Y-KVbP6QZknfadXEZ-FyiOL801tmcb6MoPLIt1GBtRzzMxYqB5y0WMAfkDOuP8wF9RdBMPWvDS7IIKC_OkWudCUCt9vi-8ARGYU9fdadf5aFadydlfMoC2c0oEek0wq9shl6f0tFxH4iEsBbG2plhHfhgHB7WME97-NbSZIM6dfFRmaj3AkU_gZXrXeRD6wSfFlbL5NZEKQdFWd05Ix8BUt1dMN_MHpAiD0GLnSSve8knOhEkT3alPDLqD0Z4qqemEbKkxRZ3MJ3oKFuKXBYY26VDZ92n-tTgubAPhQo=">factory in Sweden</a>, while partnering with Ingredion to develop a differentiated portfolio of plant-based protein isolates based on yellow peas. Construction of the production plant will be completed in 2027.

INGR

Reported Earlier, Ingredion And Lantmännen Forge Strategic Alliance To Boost European Plant-Based Protein Market, Invest Over €100M In New Pea Protein Facility

U.K. Trade Balance Non-EU For September -5.31B Vs. -4.85B (Revised) Prior

U.K. Trade Balance For September -16.32B Vs. -15.70B Est.; -15.21B (Revised) Prior

U.K. Monthly Gross Domestic Product (GDP) 3M/3M Change For September 0.1% Vs. 0.2% Est.; 0.2% Prior

U.K. Manufacturing Production (MoM) For September -1.0% Vs. 0.0% Est.; 1.3% (Revised) Prior

U.K. Industrial Production (MoM) For September -0.5% Vs. 0.1% Est.; 0.5% Prior

U.K. Gross Domestic Product (QoQ) Preliminary For Q3 0.1% Vs. 0.2% Est.; 0.5% Prior

U.K. Gross Domestic Product (YoY) Preliminary For Q3 1.0% Vs. 0.1% Est.; 0.7% Prior

U.K. Gross Domestic Product (MoM) For September -0.1% Vs. 0.2% Est.; 0.2% Prior

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: McDonald's (MCD) reported upbeat Q3 re...

McDonald's, Ford, Pfizer report Q3 earnings beats: Morning Buzz

TransMedics: Every Hero Becomes A Bore At Last

J.P. Morgan analyst Allen Gong maintained a Buy rating on TransMedics Group (TMDX – Research Report) yesterday and set a price target of $116.00. T...

TransMedics Group (TMDX) Receives a Buy from J.P. Morgan

TransMedics: Maintaining A Neutral Stance After A Difficult Q3

Warning: TMDX is at high risk of performing badly

Lord Abbett Developing Growth Fund Q3 2024 Commentary

RVT: A Small-Cap Equity Fund For Income Investors With A 7.4% Yield And 12% Discount

Bullish option flow detected in TransMedics (TMDX) Group with 5,381 calls trading, 3x expected, and implied vol increasing almost 5 points to 61.03...

TransMedics Group call volume above normal and directionally bullish

TransMedics: Overreaction To Temporary Headwinds (Rating Upgrade)

Piper Sandler Keeps Their Buy Rating on TransMedics Group (TMDX)

AAPL

ADMA

CAVA

CROX

CYBR

ENOV

ESLOY

FFIV

FROG

FSLR

GKOS

HLIT

IESC

IPGP

LKNCY

LOAR

OPRA

PIPR

PYPL

RXST

SEIC

SOFI

VRNS

ZETA

Press Releases

TransMedics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

The Ensign Group Set to Join S&P MidCap 400; Curbline Properties & TransMedics Group to Join S&P SmallCap 600

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics to Report Third Quarter 2024 Financial Results on October 28, 2024

TransMedics Reports Third Quarter 2024 Financial Results

Legal

INVESTIGATION ALERT (NASDAQ:TMDX): DiCello Levitt LLP Is Investigating Investor Claims Against TransMedics Group, Inc. and Encourages TMDX Investors with Losses to Contact the Firm

TMDX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into TransMedics Group, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

TMDX INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Announces Investigation into TransMedics Group, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into TransMedics Group, Inc. (NASDAQ: TMDX)

CCRN

CURB

ENSG

SITC

SPGI

Artivion

Alphatec Holdings

AtriCure

Axonics

Baxter Intl

Conmed

Enovis

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Integra LifeSciences Holdings Corporation - Common Stock

Integra Lifesciences

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Integer Holdings Corporation Common Stock

Integer Holdings

LeMaitre Vascular

Masimo

Inari Medical

NovoCure

Envista Holdings Corporation Common Stock

Envista Holdings

Omnicell

Penumbra

PROCEPT BioRobotics Corporation - Common Stock

PROCEPT BioRobotics

QuidelOrtho

Smith & Nephew

Teleflex

Tandem Diabetes Care, Inc. - Common Stock

Tandem Diabetes Care

Piper Sandler

Oppenheimer

JP Morgan

Canaccord Genuity

Baird

트랜스메딕스 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) 주식은 회사가 예상보다 저조한 <a href="https://www.benzinga.com/pressreleases/24/10/n41586066/transmedics-reports-third-quarter-2024-financial-results">2024년 3분기 재무 결과</a>를 발표한 후 월요일 애프터 마켓에서 22% 이상 급락했다.
<ul>
<li>3분기 매출: 1억 876만 달러, <a href="https://www.benzinga.com/calendars/earnings">예상</a> 1억 1,500만 달러 대비 하회</li>
</ul>
<ul>
<li>3분기 EPS: 12센트, <a href="https://www.benzinga.com/calendars/earnings">예상</a> 30센트 대비 하회</li>
</ul>
총 매출은 전년 대비 64% 증가했는데, 이는 주로 세 장기 모두에 걸쳐 장기 관리 시스템(Organ Care System) 활용도가 증가하고 회사의 물류 서비스에서 발생한 추가 매출에 힘입은 것이다.
트랜스메딕스는 3분기 말에 현금 3억 3,100만 달러를 보유하고 있었으며, 이는 2분기 말 3억 6,280만 달러에서 감소한 수치이다.
트랜스메딕스의 사장 겸 CEO인 왈리드 하사네인(Waleed Hassanein)은 &#8220;올해 지금까지의 실적에 자부심을 느끼며 2024년을 강한 모습으로 마무리할 것으로 기대한다&#8221;고 말했다.
그는 또한 &#8220;우리는 3분기를 통해 각 성장 이니셔티브에서 의미 있는 발전을 지속하고 있으며, 2025년 이후의 성장 잠재력에 대한 확신을 유지한다&#8221;고 덧붙였다.
추가 정보: 트랜스메딕스는 연간 매출이 4억 2,500만 달러에서 4억 4,500만 달러 사이가 될 것으로 예상하고 있으며, 이는 예상치 4억 4,436만 달러와 비교된다.
그는 &#8220;전반적으로, 우리는 2028년까지 미국에서 매년 10,000건의 OCS 이식 사례를 달성하겠다는 목표를 잘 준수하고 있다&#8221;라고 추가했다.
TMDX 주가 움직임: 트랜스메딕스의 <a href="http://benzinga.com/quote/tmdx">주식</a>은 월요일 애프터 마켓에서 22.74% 하락하여 $97.53에 거래되었다.
사진 출처: Pixabay
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

TransMedics Gr

뉴스

에 대한 최신 뉴스 TransMedics Gr (NASDAQ:TMDX) 주식

월요일, 10월 28, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌